Related references
Note: Only part of the references are listed.Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2012)
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Victoria M. Rimkunas et al.
CLINICAL CANCER RESEARCH (2012)
The transcriptional landscape and mutational profile of lung adenocarcinoma
Jeong-Sun Seo et al.
GENOME RESEARCH (2012)
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Sandrine Medves et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
Akihiko Yoshida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers
Takaaki Sasaki et al.
CLINICAL CANCER RESEARCH (2011)
High-resolution characterization of a hepatocellular carcinoma genome
Yasushi Totoki et al.
NATURE GENETICS (2011)
One size does not fit all
Christine M. Lovly et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Ting-Lei Gu et al.
PLOS ONE (2011)
Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
Ashley H. Birch et al.
PLOS ONE (2011)
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
David E. Gerber et al.
CANCER CELL (2010)
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Mari Mino-Kenudson et al.
CLINICAL CANCER RESEARCH (2010)
Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Organizing the cell cortex: the role of ERM proteins
Richard G. Fehon et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor
Byung Sun Park et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2009)
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
Kentaro Inamura et al.
MODERN PATHOLOGY (2009)
Transcriptome sequencing to detect gene fusions in cancer
Christopher A. Maher et al.
NATURE (2009)
A mouse model for EML4-ALK-positive lung cancer
Manabu Soda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
Danan Li et al.
CANCER CELL (2007)
A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays
Y Nannya et al.
CANCER RESEARCH (2005)
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
A Charest et al.
GENES CHROMOSOMES & CANCER (2003)
Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice
A Mishra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
